EGFR and neoplasm: The detection rates for TKI-sensitizing or T790M mutations in plasma were not significantly related to sex, smoking status, EGFR mutation status at diagnosis, ECOG performance status, tumor stage, immediate prior treatment regimen, or type of EGFR-TKI first administered.